Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

36.12USD
14 Dec 2018
Change (% chg)

$-1.80 (-4.75%)
Prev Close
$37.92
Open
$37.48
Day's High
$37.66
Day's Low
$35.89
Volume
73,355
Avg. Vol
108,601
52-wk High
$48.31
52-wk Low
$20.70

Latest Key Developments (Source: Significant Developments)

Xencor Q2 Loss Per Share $0.46
Monday, 6 Aug 2018 04:01pm EDT 

Xencor Inc ::XENCOR REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.46.Q2 EARNINGS PER SHARE VIEW $-0.48 -- THOMSON REUTERS I/B/E/S.EXPECT TO ANNOUNCE TOPLINE DATA FROM PHASE 2 TRIAL OF XMAB 5871 IN SLE AND INITIAL DATA FROM PHASE 1 TRIAL OF XMAB 14045 IN AML IN 4Q18.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $555.4 MILLION AS OF JUNE 30, 2018.NO REVENUES WERE REPORTED FOR THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2018.EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2023.  Full Article

Xencor Doses First Patient In Phase 1 Study Of XmAb20717 Dual Checkpoint Inhibitor
Thursday, 12 Jul 2018 04:00pm EDT 

July 12 (Reuters) - Xencor Inc ::XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB20717 DUAL CHECKPOINT INHIBITOR FOR THE TREATMENT OF ADVANCED SOLID TUMORS.XENCOR INC - BY END OF 2018, EXPECTS TO FILE IND APPLICATIONS FOR 2 ADDITIONAL TUMOR MICROENVIRONMENT ACTIVATORS.  Full Article

Xencor Reports Q1 Loss Per Share $0.62
Monday, 7 May 2018 04:01pm EDT 

May 7 (Reuters) - Xencor Inc ::XENCOR REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2023.EXPECTS TO END 2018 WITH APPROXIMATELY $500 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article

Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Xencor Inc ::XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS.XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018.  Full Article

Xencor posts Q3 loss of $0.33 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Xencor Inc :Xencor reports third quarter 2017 financial results and provides clinical pipeline update.Q3 revenue $7.1 million versus i/b/e/s view $6.3 million.Q3 loss per share $0.33.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article